發(fā)布時間：2018-05-05 01:37

  本文選題：高危局部進(jìn)展性前列腺癌 + 新輔助化療　； 參考：《上海交通大學(xué)學(xué)報(醫(yī)學(xué)版)》2017年06期

【摘要】：目的·評估高危局部進(jìn)展性前列腺癌患者行多西他賽聯(lián)合全雄阻斷新輔助治療的安全性,總結(jié)其不良反應(yīng)及臨床處理對策。方法·回顧性研究2015年6月至2017年2月55例行新輔助化療聯(lián)合全雄阻斷內(nèi)分泌治療患者的臨床資料,新輔助治療方案為基于多西他賽的3周DP方案聯(lián)合促性腺激素釋放激素類似物及雄激素阻斷劑比卡魯胺,共4周期。觀察并記錄所有治療相關(guān)不良反應(yīng)。結(jié)果·55例中2例因肝功能損害在2周期治療后退出研究。新輔助治療過程中,沒有嚴(yán)重過敏反應(yīng)發(fā)生。最常見的不良反應(yīng)為血液系統(tǒng)毒性,23.6%的患者出現(xiàn)了Ⅲ~Ⅳ級中性粒細(xì)胞減少,12.7%的患者出現(xiàn)貧血。由于療程較短,皮膚黏膜損害、外周神經(jīng)毒性及體液潴留并不多見,而全雄阻斷相關(guān)性潮熱、男性乳房發(fā)育及勃起功能障礙發(fā)生率較高。絕大多數(shù)不良反應(yīng)通過對癥支持治療可緩解。結(jié)論·在經(jīng)過嚴(yán)格選擇的局部進(jìn)展期高危前列腺癌患者中進(jìn)行4周期的新輔助化療聯(lián)合全雄阻斷內(nèi)分泌治療,不良反應(yīng)可控,但在治療期間仍需嚴(yán)密監(jiān)測并最大程度降低不良反應(yīng)發(fā)生率。此外,由全雄阻斷引起的低雄激素水平相關(guān)性內(nèi)分泌代謝紊亂也是治療過程中需要關(guān)注的問題。
[Abstract]:Objective to evaluate the safety of docetaxel combined with total male occlusion neoadjuvant therapy in patients with high risk local progressive prostate cancer. Methods the clinical data of 55 patients with neoadjuvant chemotherapy combined with total male endocrine blockade from June 2015 to February 2017 were retrospectively studied. The neo-adjuvant regimen was a 3-week DP regimen based on docetaxel combined with gonadotropin releasing hormone analogue and androgen blocker Bi amine for 4 cycles. Observe and record all treatment related adverse reactions. Results 2 out of 55 patients withdrew from the study after 2 cycles of treatment due to liver dysfunction. No severe allergic reactions occurred during neoadjuvant therapy. The most common adverse reaction was that 23. 6% of the patients with hematological toxicity had grade 鈪，

本文編號：1845615